GVAG
IMRX icon

Great Valley Advisor Group’s Immuneering IMRX Stock Holding History

Great Valley Advisor Group’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Hold
21,120
– – ﹤0.01% 1017
2026
Q1 		$112K Buy
21,120
+2,120
+11% +$10.9K ﹤0.01% 974
2025
Q4 		$125K Buy
+19,000
New +$122K ﹤0.01% 920

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Great Valley Advisor Group's IMRX Position: Q2 2026 in Review

Great Valley Advisor Group held its Immuneering (IMRX) position steady in Q2 2026 at 21,120 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #1017.

Great Valley Advisor Group first reported a position in IMRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $125K in Q4 2025. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Great Valley Advisor Group held 21,120 shares of Immuneering worth $106K as of Q2 2026.
  • Great Valley Advisor Group left its Immuneering share count unchanged in Q2 2026.
  • Immuneering made up ﹤0.01% of Great Valley Advisor Group's portfolio in Q2 2026, its #1017 holding.
  • Great Valley Advisor Group first reported a position in Immuneering in Q4 2025 and has held it in 3 quarters since.
  • Great Valley Advisor Group's Immuneering position peaked at $125K in Q4 2025.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Great Valley Advisor Group's 13F filing for Q2 2026, filed 10 Aug 2026.